Retour
Fourchette du Jour
25,82 €
27,83 €
Fourchette 52 Semaines
9,60 €
30,58 €
Volume
1 533 123
Moyenne 50J / 200J
25,21 €
/
21,69 €
Clôture Précédente
27,06 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -14,8 | 0,4 |
| P/B | 8,7 | 2,9 |
| ROE % | -73,9 | 3,8 |
| Net Margin % | — | 3,9 |
| Rev Growth 5Y % | — | 10,0 |
| D/E | 0,3 | 0,2 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 2, 2026 |
Bush Tia L
Chief Technology & Quality Ofc
|
grant | 175 000 | — | — |
| Feb 1, 2026 |
Bush Tia L
Chief Technology & Quality Ofc
|
other | 8 549 | 24,57 € | 210 049 € |
| Dec 8, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 10 000 | 9,53 € | — |
| Dec 8, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
sell | 10 000 | 30,00 € | 300 000 € |
| Nov 17, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 12 000 | 5,84 € | — |
| Nov 17, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 6 000 | 27,64 € | 165 835 € |
| Nov 1, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 593 | 24,90 € | 14 766 € |
| Sep 10, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 40 000 | 5,84 € | — |
| Sep 10, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 20 000 | 22,00 € | 440 000 € |
| Sep 9, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 40 000 | 5,84 € | — |
| Sep 9, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 20 000 | 20,01 € | 400 102 € |
| Aug 1, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 597 | 17,17 € | 10 250 € |
| Jul 29, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
sell | 8 322 | 15,23 € | 126 751 € |
| Jul 25, 2025 |
Weinhoff Gregory M
Chief Business Officer
|
other | 20 000 | 3,85 € | — |
| Jul 25, 2025 |
Weinhoff Gregory M
Chief Business Officer
|
sell | 10 000 | 15,56 € | 155 598 € |
| Jul 21, 2025 |
SAHA SAURABH
Chief Executive Officer
|
other | 110 000 | 3,85 € | — |
| Jul 21, 2025 |
SAHA SAURABH
Chief Executive Officer
|
sell | 55 000 | 15,92 € | 875 600 € |
| Jul 15, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 12 000 | 5,84 € | — |
| Jul 15, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 6 000 | 14,93 € | 89 567 € |
| Jun 24, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 30 000 | 3,85 € | — |
Points Clés
Debt/Equity of 0,29 — conservative balance sheet
Negative free cash flow of -142,09M
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-73,93%
ROIC-29,07%
Net MarginN/A
Op. MarginN/A
Sécurité
Debt / Equity
0,29
Current Ratio9,25
Interest Coverage-19,93
Valorisation
P/E Ratio
-14,79
P/B Ratio8,68
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -100,00% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -235,76M |
| ROE | -73,93% | ROA | -40,87% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -142,09M |
| ROIC | -29,07% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,29 | Current Ratio | 9,25 |
| Interest Coverage | -19,93 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -14,79 | P/B Ratio | 8,68 |
| P/S Ratio | N/A | PEG Ratio | -0,26 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 3,49B | Enterprise Value | 3,22B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 6,85M | 0,0 | 0,0 | 0,0 |
| Net Income | -235,76M | -151,09M | -216,21M | -381,90M | -10,66M |
| EPS (Diluted) | -2,06 | -1,57 | -2,31 | -4,24 | -0,08 |
| Gross Profit | 0,0 | 6,85M | 0,0 | 0,0 | 0,0 |
| Operating Income | -201,06M | -171,28M | -212,26M | -374,87M | -10,44M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 576,80M | 360,25M | 444,31M | 629,64M | 11,72M |
| Total Liabilities | 175,25M | 124,00M | 108,14M | 138,08M | 8,62M |
| Shareholders' Equity | 401,55M | 236,24M | 336,17M | 491,55M | 3,10M |
| Total Debt | 117,23M | 84,59M | 69,80M | 75,70M | 5,63M |
| Cash & Equivalents | 383,22M | 128,03M | 393,64M | 595,08M | 7,23M |
| Current Assets | 536,41M | 315,09M | 437,75M | 628,77M | 11,17M |
| Current Liabilities | 58,00M | 39,39M | 38,34M | 24,64M | 8,62M |